ArticleCell communication and signaling : CCS2025
African swine fever virus A179L inhibits interferon induced transmembrane protein 1 activation of NF-κB pathway.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploiting Ubiquitination: African Swine Fever Virus-Mediated Recruitment of Host E3 Ligases During Viral Infection and Immune Regulation.Pathogens (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
African swine fever virus (ASFV) encodes over 150 viral proteins, several of which have roles in evading innate immune responses. Among these, A179L is the only Bcl-2-like protein involved in ASFV-induced apoptosis, but its other functions remain poorly understood. This study found that A179L inhibits the NF-κB signaling pathway, reducing the production of pro-inflammatory cytokines. Mechanistically, A179L was found to interact with Interferon Induced Transmembrane Protein 1(IFITM1), leading to enhanced recruitment of MARCH8 to IFITM1 and degradation of IFITM1 by K48 ubiquitination, thereby suppressing NF-κB activation. Interestingly, it was observed for the first time that IFITM1 can activate the NF-κB signaling pathway by interacting with IKKβ and promoting its phosphorylation. Additionally, inhibiting A179L gene expression in ASFV-infected cells via RNA silencing increased the transcription levels of tumor necrosis factor-α and interleukin-1β. Subsequently, a recombinant ASFV strain, ASFV-ΔA179L, was generated by knocking out the A179L gene from the virus genome. The results demonstrated that ASFV-ΔA179L enhanced the expression of pNF-κB and pro-inflammatory cytokines. The findings of this study suggest a novel mechanism through which A179L inhibits the NF-κB signaling pathway by degrading IFITM1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.